← All trials
NCT03785106
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2019
- Primary completion
- Mar 31, 2023
- Completion date
- Mar 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 2500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- The HIV Netherlands Australia Thailand Research CollaborationLead sponsor
- HIV-NAT Thai Red Cross AIDS Research CenterOverall official - principal investigator
- KhonKaen UniversityCollaborator
- Chulalongkorn UniversityCollaborator
- The Public Health Centre 28 Krung thon buriCollaborator
- Taksin HospitalCollaborator
- Sisaket HospitalCollaborator
- Sanpatong HospitalCollaborator
- Queen Savang Vadhana Memorial Hospital, ThailandCollaborator
- Pranangklao HospitalCollaborator
- Police General HospitalCollaborator
- Maharat Nakhon Ratchasima HospitalCollaborator
- Klang HospitalCollaborator
- Hatyai HospitalCollaborator
- Chiangrai Prachanukroh HospitalCollaborator
- Buddhachinaraj HospitalCollaborator
- Bhumibol Adulyadej HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.